Functionally, PLB-1001 not only demonstrates a good BBB permeability, but also has a higher efficacy than crizotinib in inhibiting MET-driven GBM tumor growth in mice.23 Importantly, a phase I clinical trial has shown that PLB-1001 monotherapy achieved safety and a partial response for secondary GBM or grade III glioma patients with ZM fusion and/or METex14. The gene discussed is MET; the disease is glioma.